{"title":"新型抗抑郁药物的临床实用性：了解新型抗抑郁药物在治疗 MDD 中的作用。","authors":"Kristin Waters","doi":"10.9740/mhc.2022.10.309","DOIUrl":null,"url":null,"abstract":"<p><p>Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non-mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 5","pages":"309-319"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/ec/i2168-9709-12-5-309.PMC9645287.pdf","citationCount":"0","resultStr":"{\"title\":\"The clinical utility of newer antidepressant agents: Understanding the role in management of MDD.\",\"authors\":\"Kristin Waters\",\"doi\":\"10.9740/mhc.2022.10.309\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non-mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases.</p>\",\"PeriodicalId\":22710,\"journal\":{\"name\":\"The Mental Health Clinician\",\"volume\":\"12 5\",\"pages\":\"309-319\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/ec/i2168-9709-12-5-309.PMC9645287.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Mental Health Clinician\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9740/mhc.2022.10.309\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2022.10.309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
MDD 的部分特征是情绪变化，但其他症状也会造成严重损害，包括性功能障碍、认知障碍和疲劳。目前正在探索新的抗抑郁药物，目的是更有效地治疗这些与情绪无关的 MDD 症状。最近获得 FDA 批准的 3 种口服抗抑郁药包括伏替西汀、维拉唑酮和左米那西普仑。我们将通过 3 个病例来探讨这些抗抑郁药的独特之处。
The clinical utility of newer antidepressant agents: Understanding the role in management of MDD.
Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non-mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
